Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

nanoparticle formulation CPI-300

A nanoparticle-based formulation composed of a nanoscale coordination polymer (NCP) complex containing two as of yet undisclosed anti-tumor agents, with potential antineoplastic activities. Upon intravenous administration, nanoparticle formulation CPI-300 delivers the anti-tumor agents to tumor cells, which may lead, through as of yet undisclosed mechanism of actions (MoAs), to specific tumor cell killing and inhibition of proliferation of tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	nanoscale coordination polymer-based formulation CPI-300 NCP platform-based CPI-300
Code name:	CPI 300 CPI-300 CPI300

nanoparticle formulation CPI-300

Search NCI's Drug Dictionary